Answers are grounded in this paper and cite their sources.
Recent Medicines and Healthcare products Regulatory Agency (MHRA) isotretinoin legislation includes significant changes that will affect clinical practice for dermatologists across the UK. We obtained opinions from members of the Scottish Dermatological Society on these recommendations. The survey yielded an adequate number of responses with significant results and free-text comments of interest to practising UK dermatologists. Overall responses from SDS members highlighted many concerns with the MHRA guidance and its impact on patient care. The results of this survey question the credibility of the MHRA. We propose the creation of an objective working group, with no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Dubash et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: